CareDx Announces Largest Landmark Study of Its Kind on Antibody Mediated Rejection in Heart Transplantation Published in Journal of the American College of Cardiology: Heart Failure
CareDx, Inc. (CDNA)
Last caredx, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.caredxinc.com
Company Research
Source: Business Wire
Second SHORE Study Validates AlloSure Heart, an Integral Component of HeartCare, as a Reliable Biomarker for Antibody-Mediated Rejection in Heart Transplant Recipients SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the publication of the second study from Surveillance HeartCare Outcomes Registry (SHORE) in the Journal of the American College of Cardiology: Heart Failure. It is the largest prospective analysis of antibody-mediated rejection (AMR) in heart transplantation, including 2,240 patients across 59 U.S. transplant centers and analyzing 24,768 biopsies, 8,851 paired donor-derived cell-free DNA (dd-cfDNA) samples measured using AlloSure® Heart, and 136 AMR-positive biopsies paired with dd-cfDNA results. AlloSure, in combination with Al
Show less
Read more
Impact Snapshot
Event Time:
CDNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDNA alerts
High impacting CareDx, Inc. news events
Weekly update
A roundup of the hottest topics
CDNA
News
- SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung TransplantationBusiness Wire
- CareDx (NASDAQ:CDNA) had its "hold (c-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- CareDx (NASDAQ:CDNA) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.MarketBeat
- CareDx to Participate in Upcoming Investor ConferencesBusiness Wire
- CareDx (NASDAQ:CDNA) was upgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "sell (d+)" rating to a "hold (c-)" rating.MarketBeat
CDNA
Earnings
- 11/4/25 - Beat
CDNA
Sec Filings
- 12/5/25 - Form 4
- 12/4/25 - Form 144
- 11/14/25 - Form SCHEDULE
- CDNA's page on the SEC website